Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | WRN | Q14191 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16722564 | 0.86 | KCNQ3 (0.49) | GRM4ALDH1A1LRRK2NPC1RAB9A | |
| SCHEMBL3554749 | 0.85 | ALDH1A1 (0.63) | GRM4BLMWRNALDH1A1NPC1 | |
| SCHEMBL25003490 | 0.84 | GRM4 (0.61) | GRM4BLMWRNALDH1A1NPC1 | |
| SCHEMBL2714906 | 0.83 | GRM4 (0.43) | GRM4BLMWRNNPC1RAB9A | |
| SCHEMBL12777490 | 0.82 | GRM4 (0.56) | GRM4BLMWRNALDH1A1AR | |
| SCHEMBL3008351 | 0.82 | GRM4 (0.56) | GRM4BLMWRNALDH1A1KCNH2 | |
| SCHEMBL29824380 | 0.82 | GRM4 (0.56) | GRM4BLMWRNALDH1A1KCNH2 | |
| SCHEMBL7930452 | 0.81 | GRM4 (0.54) | GRM4BLMWRNKCNH2AR | |
| SCHEMBL4219043 | 0.81 | GRM4 (0.54) | GRM4BLMWRNALDH1A1KCNH2 | |
| SCHEMBL31703118 | 0.81 | GRM4 (0.58) | GRM4BLMWRNALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-19 | — | — | US | disclosed |
| EP-3976619-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| CN-113939511-A | Difluoroazepane as HBV capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113906031-A | Fused heterocyclic derivatives as capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113906028-A | Fused heterocyclic derivatives | 爱尔兰詹森科学公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113891889-A | Diazepinone derivatives as capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-109641896-B | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239864-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | ZC3HAV1, CALM1, ZC3HAV1L | GRM4 2544/4885BLM 2518/4885WRN 3063/4885 |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | GRM4 1217/4885BLM 4163/4885WRN 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.